29 January 2021 - The recommendations from the December 2020 PBAC meeting are now available.

The PBAC recommended:

• Glecaprevir with pibrentasvir (Maviret) - restriction change (duration of treatment reduced from 12 weeks to 8 weeks for treatment naïve patients with chronic hepatitis C with compensated cirrhosis)
  
• Sapropterin dihydrochloride (Kuvan) - new indication (maternal phenylketonuria)

The Committee rejected MSD's submissions for Hadlima (adalimumab) and Brenzys (etanercept). The submissions had multiple requests:

• An Authority Required (STREAMLINED) listing for adalimumab/etanercept in the continuing treatment phase
  
• An Authority Required (Telephone/Online) for adalimumab/etanercept in the initial treatment phase
  
• That use of adalimumab/etanercept not count as a treatment failure
  

The PBAC also rejected the PBS listing of laretrectinib sulphate (VitrakvI) for the treatment of patients with a solid tumour harbouring a neurotrophic receptor tyrosine kinase gene fusion on the basis that the incremental cost effectiveness ratio was unacceptably high and uncertain at the price proposed. The PBAC wants a price reduction.

Read PBAC outcomes